AUTL:NSD-Autolus Therapeutics Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 3.99

Change

0.00 (0.00)%

Market Cap

USD 1.06B

Volume

1.02M

Analyst Target

USD 26.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-12 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+8.09 (+1.70%)

USD 117.92B
REGN Regeneron Pharmaceuticals Inc

+12.58 (+1.27%)

USD 108.54B
MRNA Moderna Inc

+9.50 (+6.54%)

USD 63.85B
BNTX BioNTech SE

+3.02 (+3.04%)

USD 22.68B
ARGX argenx NV ADR

+6.42 (+1.70%)

USD 22.66B
ALNY Alnylam Pharmaceuticals Inc

+2.30 (+1.54%)

USD 18.94B
GMAB Genmab AS

+0.24 (+0.84%)

USD 18.15B
BGNE BeiGene Ltd

+3.94 (+2.54%)

USD 17.32B
RPRX Royalty Pharma Plc

-0.02 (-0.07%)

USD 15.90B
BMRN Biomarin Pharmaceutical Inc

+0.58 (+0.73%)

USD 14.34B

ETFs Containing AUTL

HOML 8.77 % 0.00 %

N/A

N/A
CLAW 6.09 % 0.95 %

N/A

N/A
FOVL iShares Focused Value Fac.. 3.41 % 0.25 %

+0.37 (+1.28%)

USD 0.02B
XMMO Invesco S&P MidCap Moment.. 2.26 % 0.39 %

+2.29 (+1.28%)

USD 2.86B
PAMC Pacer Lunt MidCap Multi-F.. 2.03 % 0.00 %

+0.50 (+1.28%)

USD 0.06B
HOMZ The Hoya Capital Housing .. 1.88 % 0.00 %

+0.38 (+1.28%)

USD 0.04B
VAMO 1.51 % 0.64 %

N/A

N/A
ZEUS:CA 1.40 % 0.73 %

N/A

N/A
AFMC First Trust Active Factor.. 1.09 % 0.00 %

+0.31 (+1.28%)

USD 0.01B
EZM WisdomTree U.S. MidCap Ea.. 0.97 % 0.38 %

+0.56 (+1.28%)

USD 0.79B
ISCV iShares Morningstar Small.. 0.62 % 0.00 %

+0.52 (+1.28%)

USD 0.41B
FSMD Fidelity Small-Mid Factor 0.34 % 0.00 %

+0.38 (+1.28%)

USD 0.33B
ISCB iShares Morningstar Small.. 0.31 % 0.00 %

+0.69 (+1.28%)

USD 0.22B
WDSC:LSE SPDR MSCI World Small Cap.. 0.19 % 0.00 %

+0.39 (+1.28%)

USD 0.84B
WOSC:LSE SPDR MSCI World Small Cap.. 0.19 % 0.00 %

+0.42 (+1.28%)

USD 0.84B
WLDS:LSE iShares MSCI World Small .. 0.17 % 0.00 %

+0.03 (+1.28%)

USD 3.90B
WSML:LSE iShares MSCI World Small .. 0.17 % 0.00 %

+0.03 (+1.28%)

USD 3.90B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -38.04% 21% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.04% 21% F 14% F
Trailing 12 Months  
Capital Gain 94.63% 90% A- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 94.63% 90% A- 94% A
Trailing 5 Years  
Capital Gain -83.26% 37% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -83.26% 37% F 14% F
Average Annual (5 Year Horizon)  
Capital Gain -5.27% 52% F 33% F
Dividend Return -5.27% 52% F 31% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 78.05% 35% F 21% F
Risk Adjusted Return -6.76% 53% F 37% F
Market Capitalization 1.06B 83% B 73% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector